Be (not too) still my heart: Kestra Medical Technologies Ltd., maker of a wearable cardioverter defibrillator for patients at high risk of cardiac arrest, filed an S-1 with the U.S. SEC on Feb. 9 to raise $100 million in an IPO. Kestra will be the fourth med-tech company to file for an IPO in 2025, setting a pace well ahead of the last three years. U.s.car
Microglia play a crucial role in neuroinflammation after ischemic brain injury. Previous data have shown that leukocyte immunoglobulin-like receptor B4 (LILRB4) was upregulated in mice after middle cerebral artery occlusion (MCAO), but the role it plays here is not well understood. The role LILRB4 plays in ischemic brain injury was thus investigated. LILRB4 expression was measured in mice at different time points after MCAO.
Olix Pharmaceuticals Inc. walked the talk in realizing a new $630 million licensing deal with Eli Lilly and Co. for its cardiovascular and metabolic disease asset, OLX-702A (OLX-75016), rallying stock by 30% after it had largely recovered from a terminated deal with France’s Théa Open Innovation last year.
A 1,000-person study using Heartflow Inc. technology demonstrated that findings of coronary plaque on heart CT scans could indicate which patients were at risk of cardiovascular events up to seven years in the future – potentially providing a road map toward screening for heart disease, the leading cause of death for both men and women in the U.S. and worldwide.
The U.S. national coverage analysis for transcatheter tricuspid valve replacement drew support from cardiologists and device makers alike, but the Medical Device Manufacturers Association is urging CMS to plan ahead in its final coverage memo and consider the coverage needs outside the confines of the existing U.S. FDA-approved device.
The med tech patent wars conscripted another two companies via a patent infringement lawsuit between Inari Medical Inc. and Imperative Care Inc. — a struggle that is playing out in a California district court.
Early dysfunction of the endothelial/blood-brain barrier (BBB) is involved in the pathogenesis of cerebral small vessel disease (SVD), which is a contributor to about 50% of dementias. Sphingosine-1-phosphate (S1P) is a sphingolipid that regulates the BBB integrity when bound to its receptor S1P1 on endothelial cells.
As pulsed field ablation transformed the electrophysiology market over the last year, Boston Scientific Corp. emerged as the biggest winner by far. In its fourth quarter earnings call on Wednesday, the company quantified just how successful its Farapulse PFA system has been.
Researchers from Sun Yat-sen University and affiliated organizations published data from a study that aimed to assess the role of the TNF receptor-associated factor 6 (TRAF6), E3 ubiquitin ligase previously shown to be involved in cardiovascular diseases, in formation of abdominal aortic aneurysm (AAA).
Myocardial infarction remains one of the leading causes of mortality, which is usually complicated by the occurrence of ischemic ventricular arrhythmias, which in turn increase the risk of sudden cardiac death in patients with myocardial infarction.
RSS
